GlassScriptPhysician profile
Helen M Kiomento
NPI 1316927106
$2,626.73
in general payments reported to CMS, 2019-2025
33 companies · $408 in 2025
The $408 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $288 · 2020: $197 · 2021: $121 · 2022: $302 · 2023: $646 · 2024: $665 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,719.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $685.56 | 2021-2025 | |
| Pfizer INC. | $323.39 | 2019-2025 | |
| Glaxosmithkline, LLC. | $186.61 | 2020-2024 | Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.16 | 2020-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Novo Nordisk INC | $177.17 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $157.25 | 2020-2025 | Repatha, Otezla, Prolia |
| Astrazeneca Pharmaceuticals LP | $100.79 | 2019-2024 | Farxiga |
| Lilly USA, LLC | $88.85 | 2019-2025 | Jardiance, Amyvid, Kisunla |
| Merck Sharp & Dohme LLC | $80.62 | 2019-2024 | Vaxneuvance, Capvaxive, Gardasil 9 |
| Novartis Pharmaceuticals Corporation | $57.61 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $54.71 | 2019-2024 | Eliquis |
| Radius Health, INC. | $54.01 | 2020-2024 | Tymlos |
| Sanofi Pasteur INC. | $43.22 | 2022-2023 | |
| Neurocrine Biosciences, INC. | $37.00 | 2019-2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $34.30 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $33.93 | 2022-2024 | |
| Indivior INC. | $31.87 | 2024 | Sublocade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.05 | 2019-2023 | Xifaxan |
| Supernus Pharmaceuticals, INC. | $29.57 | 2020 | |
| Amarin Pharma, INC. | $28.27 | 2020 | |
| Dexcom, INC. | $21.21 | 2024 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $19.49 | 2025 | Rexulti |
| Sumitomo Pharma America, INC. | $19.41 | 2024 | Gemtesa |
| Exact Sciences Corporation | $19.18 | 2023 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $18.30 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.23 | 2020 | |
| Antares Pharma, INC. | $15.25 | 2025 | Xyosted |
| Avanir Pharmaceuticals, INC. | $15.09 | 2019 | |
| Horizon Therapeutics Plc | $14.83 | 2019 | |
| Shield Therapeutics INC | $13.52 | 2024 | |
| Abbott Laboratories | $13.20 | 2022 | |
| Allergan, INC. | $12.15 | 2019 | |
| Vertiflex, INC. | $11.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helen Kiomento listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.